Show simple item record

Celiprolol double-peak occurrence and gastric motility: Nonlinear mixed effects modeling of bioavailability data obtained in dogs

dc.contributor.authorLipka, Elkeen_US
dc.contributor.authorLee, I-Deren_US
dc.contributor.authorLangguth, Peteren_US
dc.contributor.authorSpahn-Langguth, Hildegarden_US
dc.contributor.authorMutschler, Ernsten_US
dc.contributor.authorAmidon, Gordon L.en_US
dc.date.accessioned2006-09-11T15:36:44Z
dc.date.available2006-09-11T15:36:44Z
dc.date.issued1995-06en_US
dc.identifier.citationLipka, Elke; Lee, I-Der; Langguth, Peter; Spahn-Langguth, Hildegard; Mutschler, Ernst; Amidon, Gordon L.; (1995). "Celiprolol double-peak occurrence and gastric motility: Nonlinear mixed effects modeling of bioavailability data obtained in dogs." Journal of Pharmacokinetics and Biopharmaceutics 23(3): 267-286. <http://hdl.handle.net/2027.42/45049>en_US
dc.identifier.issn1573-8744en_US
dc.identifier.issn0090-466Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45049
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8834196&dopt=citationen_US
dc.description.abstractInvestigation of the underlying mechanism leading to inter- and intrasubject variations in the plasma concentration-time profiles of drugs (1) can considerably benefit rational drug therapy. The significant effect of gastric emptying on the rate and extent of celiprolol absorption and its role with respect to double-peak formation was demonstrated in the present study. In four dogs racemic celiprolol was dosed perorally in a crossover design during four different phases of the fasted-state gastric cycle and gastric motility was recorded simultaneously using a manometric measurement system. Intravenous doses were also given to obtain disposition and bioavailability parameters. The blood samples were assayed by a stereoselective HPLC method (2). The time to onset of the active phase of the gastric cycle showed an excellent correlation with the time to celiprolol peak concentration. Furthermore, bioavailability was increased when celiprolol was administered during the active phase. Double peaks were observed when the first active phase was relatively short, suggesting that a portion of the drug remained in the stomach until the next active phase. Population pharmacokinetic modeling of the data with a two-compartment open model with two lag times incorporating the motility data confirmed the effect of time to gastric empyting on the variability of the oral pharmacokinetics of celiprolol. The fasted-state motility phases determine the rate and extent of celiprolol absorption and influence the occurrence of double peaks. Peak plasma levels of celiprolol exhibit less variability if lag times, and therefore gastric emptying times, are taken into consideration.en_US
dc.format.extent966412 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Mediaen_US
dc.subject.otherVariable Oral Pharmacokineticsen_US
dc.subject.otherNONMEMen_US
dc.subject.otherGastric Motilityen_US
dc.subject.otherPharmacyen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherVeterinary Medicineen_US
dc.subject.otherBiochemistry, Generalen_US
dc.subject.otherBiomedical Engineeringen_US
dc.subject.otherCeliprololen_US
dc.subject.otherDouble-peak Phenomenonen_US
dc.subject.otherNonlinear Oral Bioavailabilityen_US
dc.subject.otherGastric Emptyingen_US
dc.subject.otherBiomedicineen_US
dc.titleCeliprolol double-peak occurrence and gastric motility: Nonlinear mixed effects modeling of bioavailability data obtained in dogsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumCollege of Pharmacy, University of Michigan, 48109, Ann Arbor, Michiganen_US
dc.contributor.affiliationumCollege of Pharmacy, University of Michigan, 48109, Ann Arbor, Michigan; Clinical Pharmacology Department, Hoechst-Roussel Pharmaceuticals, Route 202-206, 08876, Somerville, New Jerseyen_US
dc.contributor.affiliationumCollege of Pharmacy, University of Michigan, 48109, Ann Arbor, Michigan; Department of Pharmacy, ETH, CH-8093, Zuerich, Switzerlanden_US
dc.contributor.affiliationumCollege of Pharmacy, University of Michigan, 48109, Ann Arbor, Michigan; Department of Pharmacology, Johann Wolfgang Goethe-University, Biocenter, Niederursel, Marie-Curie-Strasse 9, Geb. N260, D-60439, Frankfurt/Main, Germany; TSRL Inc., 540 Avis Drive, Suite A, 48108, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDepartment of Pharmacology, Johann Wolfgang Goethe-University, Biocenter, Niederursel, Marie-Curie-Strasse 9, Geb. N260, D-60439, Frankfurt/Main, Germanyen_US
dc.contributor.affiliationotherDepartment of Pharmacology, Johann Wolfgang Goethe-University, Biocenter, Niederursel, Marie-Curie-Strasse 9, Geb. N260, D-60439, Frankfurt/Main, Germanyen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid8834196en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45049/1/10928_2006_Article_BF02354285.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF02354285en_US
dc.identifier.sourceJournal of Pharmacokinetics and Biopharmaceuticsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.